Compare TG Therapeutics Inc (TGTX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? TG Therapeutics Inc trades at $55.24 (market cap $8.16B), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| TGTX | XLP | |
|---|---|---|
Market Cap | $8.16B | $13.50B |
Volume | 1,735,121 | 14,599,953 |
Sector | Health | — |
52-Week High | $59.06 | $90.00 |
52-Week Low | $26.94 | $75.61 |
Typical Hold Time | 16 Days | 72 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.41, up 2.09% with bullish technical signals from moving averages and oscillators. The ETF shows strong relative performance, gaining 6.6% year-to-date while consumer discretionary stocks declined. Analyst sentiment is unanimously positive with 100% buy ratings, supported by the fund's low 0.08% expense ratio and defensive positioning during market volatility.
The outlook remains favorable given XLP's defensive characteristics amid economic uncertainty, though rising interest rates pose a headwind. The ETF's focus on household staples provides stability, with dividend income adding to total return potential. Key risks include inflation pressures and consumer spending shifts toward value-oriented options.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
